Liquidia reported higher YUTREPIA volume and companywide profit.
Revenue for the six months ended June 30 jumped from $8.8 million to $171.7 million, sending operating income from a $37.5 million loss to $85.5 million of profit. Net income swung to $74.7 million, and operating cash flow went from negative $70.2 million to positive $133.2 million.
That is the easy reading. The harder one sits in the balance sheet: accounts receivable rose from $10.0 million to $108.6 million, while inventory climbed from $6.4 million to $36.2 million. Liquidia generated cash, but the commercial scale-up also left much more of the business recorded as money owed by customers and products held for sale.
Management attributes the cited revenue increase to higher volume.
"The increase of $10.6 million was primarily due to higher volume of YUTREPIA sales ."
Liquidia, 10-Q filed Aug. 12, 2026.
The filing’s revenue discussion covers only the increase cited in that passage, while the six-month comparison shows the much larger step up in total sales. The business has moved from development-stage economics into commercialization economics, with the working-capital plumbing now visible in the numbers.
Cash generation also came with a qualification. Liquidia said the increase in operating cash flow reflected adjusted net income, offset by unfavorable working-capital changes of $12.8 million.
"The increase was primarily due to $216.1 million higher net income adjusted for non-cash items offset by unfavorable working capital changes of $12.8 million."
Liquidia, 10-Q filed Aug. 12, 2026.
The filing describes a profitable period in which working capital took a measurable bite. Capital spending rose from $1.4 million to $14.1 million, but capex remained a smaller slice of the much larger revenue base. The more immediate question is whether receivables and inventory settle into a repeatable rhythm as YUTREPIA sales grow.
The pipeline is getting more expensive at the same time. Research and development expense increased $16.8 million, or 129%, led by clinical expenses for L606, additional YUTREPIA work, higher headcount, and a $1.0 million L606 development milestone.
"The increase of $16.8 million or 129% was primarily due to a $9.6 million increase in clinical expenses for our L606 program, a $3.8 million increase in expenses related to our YUTREPIA research and development activities, a $2.0 million increase in personnel expenses driven by higher headcount, and a $1.0 million L606 development milestone recognized during the second quarter of 2026."
Liquidia, 10-Q filed Aug. 12, 2026.
The filing therefore describes two businesses expanding at once: YUTREPIA is producing commercial volume, while L606 and related research are consuming more resources. Diluted shares also rose 18.5% year over year, adding another piece to the arithmetic behind the per-share result.
One disclosed outside pressure concerns United Therapeutics, a competitor that Liquidia says may challenge YUTREPIA’s continued commercialization through patent and FDA-related actions. That does not explain the current sales figures, but it places a specific legal and regulatory condition alongside the product’s early commercial ramp.
At the latest close, Liquidia shares were $88.09, down 3.3% for the day, after rising 107.8% over six months. The market value was $7.6 billion, or 46.7 times the latest annual sales; the filing also details cash collection through receivables.
Liquidia has reported higher YUTREPIA volume alongside companywide revenue, profit, and operating cash in the latest six months. Its unanswered question is how much of the $108.6 million in receivables becomes cash in the next report.
Liquidia’s six-month report records higher YUTREPIA volume, $133.2 million of operating cash flow, and $108.6 million of accounts receivable.